Ovarian cancer screening in the general population

Abstract Background Ovarian carcinoma is a poor prognosis cancer mainly due to its late diagnosis. Its incidence is relatively low but mortality is high. The symptomatology is only slightly specific, which complicates diagnostic management. It would therefore be interesting to be able to establish a diagnosis as early as possible in order to improve the prognosis of patients suffering from ovarian cancer. Materials and methods Currently, the combination of an ultrasound examination with a cancer antigen (CA)-125 assay is the most effective diagnostic technique, but not already admitted as a screening method. Therefore, we realized an exhaustive analysis of the most important studies in the last 15 years, in order to find new approaches in ovarian cancer screening. Results The age for initiating screening and its frequency are issues that are not fully resolved. The false positives and morbidity that result from screening are currently notable limitations. Conclusions The latest data do not support effective screening in the general population.

[1]  Steven J Skates,et al.  Screening for ovarian cancer: a pilot randomised controlled trial , 1999, The Lancet.

[2]  N. Urban,et al.  Development of an ovarian cancer symptom index , 2007 .

[3]  N. Dubrawsky Cancer statistics , 1989, CA: a cancer journal for clinicians.

[4]  Matthew Burnell,et al.  Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) , 2009, Journal of Family Planning and Reproductive Health Care.

[5]  E. Fung,et al.  A recipe for proteomics diagnostic test development: the OVA1 test, from biomarker discovery to FDA clearance. , 2010, Clinical chemistry.

[6]  I. Jacobs,et al.  Psychological morbidity associated with ovarian cancer screening: results from more than 23 000 women in the randomised trial of ovarian cancer screening (UKCTOCS) , 2014, BJOG : an international journal of obstetrics and gynaecology.

[7]  D. Fishman,et al.  Biomarkers for Early Detection of Ovarian Cancer , 2013, Women's health.

[8]  R. Berkowitz,et al.  Intraepithelial Carcinoma of the Fimbria and Pelvic Serous Carcinoma: Evidence for a Causal Relationship , 2007, The American journal of surgical pathology.

[9]  M. Pike,et al.  Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case–control studies , 2012, The Lancet. Oncology.

[10]  D. Landsittel,et al.  Circulating IL-8 and anti-IL-8 autoantibody in patients with ovarian cancer. , 2006, Gynecologic oncology.

[11]  K. Kinzler,et al.  Evaluation of DNA from the Papanicolaou Test to Detect Ovarian and Endometrial Cancers , 2013, Science Translational Medicine.

[12]  A. Whittemore,et al.  Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. Collaborative Ovarian Cancer Group. , 1992, American journal of epidemiology.

[13]  B. Goff,et al.  Symptoms associated with ovarian cancer. , 2012, Clinical obstetrics and gynecology.

[14]  D. Bowen,et al.  Changes in cancer worry associated with participation in ovarian cancer screening , 2007, Psycho-oncology.

[15]  B. Goff,et al.  Frequency of symptoms of ovarian cancer in women presenting to primary care clinics. , 2004, JAMA.

[16]  Figo Guidelines Staging classification for cancer of the ovary, fallopian tube, and peritoneum☆ , 2013 .

[17]  D. Clarke‐Pearson,et al.  Screening for Ovarian Cancer , 2009 .

[18]  R. Dworkin,et al.  Reporting of primary analyses and multiplicity adjustment in recent analgesic clinical trials: ACTTION systematic review and recommendations , 2014, PAIN®.

[19]  L. Humphrey,et al.  Screening pelvic examination in adult women: a clinical practice guideline from the American College of Physicians. , 2014, Annals of internal medicine.

[20]  C. Crum Intercepting pelvic cancer in the distal fallopian tube: Theories and realities , 2009, Molecular oncology.

[21]  A. Berg U.S. Preventive Services Task Force , 2004 .

[22]  Nikki A. Hawkins,et al.  Physician characteristics and beliefs associated with use of pelvic examinations in asymptomatic women. , 2012, Preventive medicine.

[23]  V. Moyer,et al.  Screening for Ovarian Cancer: U.S. Preventive Services Task Force Reaffirmation Recommendation Statement , 2012, Annals of Internal Medicine.

[24]  O. Lapaire,et al.  The special role of ultrasound for screening, staging and surveillance of malignant ovarian tumors: distinction from other methods of diagnostic imaging , 2014, Archives of Gynecology and Obstetrics.

[25]  A. Tinker,et al.  Prophylactic Salpingectomy and Delayed Oophorectomy as an Alternative for BRCA Mutation Carriers , 2013, Obstetrics and gynecology.

[26]  William L. Bigbee,et al.  Multiplexed Immunobead-Based Cytokine Profiling for Early Detection of Ovarian Cancer , 2005, Cancer Epidemiology Biomarkers & Prevention.

[27]  Jaime Prat,et al.  Staging classification for cancer of the ovary, fallopian tube, and peritoneum , 2014, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[28]  A. Jemal,et al.  Cancer Statistics, 2009 , 2009, CA: a cancer journal for clinicians.

[29]  L. Tanoue Cancer Statistics, 2009 , 2010 .

[30]  Robert L Coleman,et al.  SGO White Paper on ovarian cancer: etiology, screening and surveillance. , 2010, Gynecologic oncology.

[31]  J. Sheeder,et al.  Risk-Reducing Salpingectomy as Preventative Strategy for Pelvic Serous Cancer , 2013, International Journal of Gynecologic Cancer.

[32]  J. Marks,et al.  Development of a multimarker assay for early detection of ovarian cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  Daniel W Chan,et al.  Combining multiple serum tumor markers improves detection of stage I epithelial ovarian cancer. , 2007, Gynecologic oncology.

[34]  S. Fegan Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) , 2009, Journal of Family Planning and Reproductive Health Care.

[35]  M. Markman Development of an ovarian cancer symptom index: Possibilities for earlier detection , 2007, Cancer.

[36]  C. Johannes,et al.  Re: "Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women". , 1993, American journal of epidemiology.